Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805
正文 · 中文译文
仿制药计划活动报告 | FDARA 第八编第807和805节 《2017年FDA再授权法案》(FDARA)第807节要求FDA报告某些简略新药申请(ANDA)。 仿制药使用者付费修正案 GDUFA IV再授权 ANDA前计划 ANDA评估计划 受控通信 药物主文件(DMF)评估 设施变更 使用者付费资源管理计划 《2017年FDA再授权法案》(FDARA)第807节要求FDA报告根据《联邦食品、药品和化妆品(FD&C)法案》第505(j)(11)节接受优先审评的某些简略新药申请(ANDA),以及根据FD&C法案第506H节获得竞争性仿制药治疗认定的某些ANDA。下表提供了这两个类别中在每个报告季度末等待FDA采取行动或等待申请人采取行动的ANDA总数数据,以及每个报告季度内这两个类别中获批的ANDA数量。以下报告的数字仅反映已根据FD&C法案第505(j)节接收以供审评的ANDA;如果新的ANDA提交在报告季度末尚未被接收以供审评,即FDA尚未就该提交是否实质完整作出门槛判定,则将在其被接收以供审评后的下一季度报告。 FDARA第805条要求FDA在根据第807条提交的报告中纳入一份年度报告,说明根据FD&C法案第505(j)(2)(c)条待审的申请(通常称为适宜性申请)的数量,以及自收到之日起待实质答复超过180天的此类申请的数量。该信息按财政年度列于下文最后一个表格中。 可获取的报告 2026财年根据FD&C法案第505(j)(11)条适用优先审评的ANDA 2026财年根据FD&C法案第506H条获得竞争性仿制药治疗认定的ANDA 2026财年根据FD&C法案第506H条获得竞争性仿制药治疗认定且部长已依据第506H(c)条采取行动的ANDA 2026财年根据FD&C法案第505(j)(2)(c)条待审的适宜性申请 以往活动报告 有关FDA仿制药办公室活动的更多数据可在此处获取。 注:数字反映发布时的当前数据,可能会根据我们追踪系统中更新后的计数而变化。 2026财年根据FD&C法案第505(j)(11)*条适用优先审评的ANDA 第一季度第二季度第三季度第四季度 10月-12月1月-3月4月-6月7月-9月 等待FDA采取行动的ANDA47494848 等待申请人采取行动的ANDA41433833 已批准的ANDA66108 *本表中的计数包括根据《联邦食品、药品和化妆品法案》(FD&C Act)第505(j)(11)条(A)项和(D)项享有优先审评的简化新药申请(ANDA),该条款由2017年《食品药品管理局再授权法案》(FDARA)第801条增补。 根据FD&C法案第506H条获得竞争性仿制药疗法认定的2026财年ANDA 第一季度第二季度第三季度第四季度 10月-12月1月-3月4月-6月7月-9月 等待FDA采取行动的ANDA178179171173 等待申请人采取行动的ANDA178179186186 已批准的ANDA20212719 申请的提交前会议数量0010 已举行的提交前会议数量0000 申请的产品开发会议数量2313 已举行的产品开发会议数量2222 根据FD&C法案第506H条获得竞争性仿制药疗法认定、且部长已依据第506H(c)条采取行动的2026财年ANDA* 第一季度第二季度第三季度第四季度 10月-12月1月-3月4月-6月7月-9月 已批准的ANDA1*3*2*2* FDARA第807(5)条要求FDA在本报告中纳入关于FD&C法案第506H条可能对获得CGT认定的ANDA的批准时长和审评周期数量产生影响的信息,FDA已依据FD&C法案第506H(c)条对这些ANDA采取行动。如FDA在《竞争性仿制药疗法行业指南》中所解释的,FDA为加快开发可采取的行动包括(视情况而定)产品开发会议和提交前会议,FDA为加快审评可采取的行动包括审评周期中期会议、强化审评周期中期会议,以及尽速对ANDA采取行动,包括在GDUFA目标日期之前。2026财年,有八项获得CGT认定且FDA已采取行动以加快申请开发和审评的ANDA获批;具体而言,我们在ANDA提交前与申请人举行了产品开发会议,在首个审评周期内与其中三位申请人举行了审评周期中期会议,并采取行动加快ANDA的审评。 在没有更大样本量的申请(包括未采取加快开发和审评措施的可比产品申请作为对照组)的情况下,很难评估为加快这些细胞和基因治疗(CGT)产品的开发和审评所采取的行动对获批所需时间长度和获批审评周期数量的影响。然而,我们注意到,其中7项简化新药申请(ANDA)在经历两个或更少审评周期后即获批,且这些ANDA的获批时间快于其获批所在季度的平均获批时间。其中,还有4项的获批时间快于其获批所在季度的获批时间中位数。通过我们的ANDA前计划,这些ANDA的申请人能够就与其ANDA开发计划相关的特定科学问题或疑问获得有针对性的反馈。获得FDA此类针对性建议的机会很可能缩短了ANDA的开发时间,并使申请人避免了可能导致ANDA获批延迟的缺陷。 FY 2026 根据《联邦食品、药品和化妆品法案》第505(j)(2)(C)条待处理的适用性请愿书+ FY 2026 待FDA实质性回应的请愿书122 收到后超过180天仍待FDA实质性回应的请愿书**61 +这些数字每年报告一次,并将在可用时发布。 **请注意,2024财年之前提交的申请未获得目标日期。关于仿制药计划在适用目标日期的适宜性申请方面的表现信息(该目标日期自2024财年提交的申请起开始适用)将纳入年度GDUFA绩效报告。 以往活动报告 仿制药计划活动报告——FDARA第八编第807条和第805条(2025财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2024财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2023财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2022财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2021财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2020财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2019财年) 仿制药计划活动报告——FDARA第八编第807条和第805条(2018财年) 内容更新日期: 2026年11月12日 受监管产品 药品
正文 · 英文原文
Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805 Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs). Generic Drug User Fee Amendments GDUFA IV Reauthorization Pre-ANDA Program ANDA Assessment Program Controlled Correspondence Drug Master File (DMF) Assessments Changes for Facilities User Fee Resource Management Program Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs) subject to priority review under section 505(j)(11) of the Federal Food, Drug, and Cosmetic (FD&C) Act and certain ANDAs with a competitive generic therapy designation under section 506H of the FD&C Act. The tables below provide data on the total number of ANDAs in these two categories that are either awaiting FDA action or awaiting applicant action at the end of each reporting quarter, as well as the number of ANDAs approved in each of these categories during the reporting quarter. The numbers reported below only reflect ANDAs that have been received for review pursuant to section 505(j) of the FD&C Act; if a new ANDA submission has not yet been received for review at the end of the reporting quarter, meaning FDA has not yet made a threshold determination whether the submission is substantially complete, it will be reported in the next quarter after it is received for review. Section 805 of FDARA requires FDA to include in the reports under section 807 an annual report on the number of pending petitions under section 505(j)(2)(c) of the FD&C Act (commonly referred to as suitability petitions) and the number of such petitions pending a substantive response for more than 180 days from the date of receipt. This information is provided by fiscal year in the last table below. Reports Available FY 2026 ANDAs Subject to Priority Review under Section 505(j)(11) of the FD&C Act FY 2026 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act FY 2026 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act for which the Secretary has taken action pursuant to Section 506H (c) FY 2026 Pending Suitability Petitions under Section 505(j)(2) (c) of the FD&C Act Previous Activities Reports Additional data on the activities of FDA’s Office of Generic Drugs is available here . NOTE: Numbers reflect current data at the time of posting and may change based on refreshed counts in our tracking systems. FY 2026 ANDAs Subject to Priority Review under Section 505(j)(11)* of the FD&C Act First QuarterSecond QuarterThird QuarterFourth Quarter October - DecemberJanuary - MarchApril - JuneJuly - September ANDAs Awaiting FDA Action47494848 ANDAs Awaiting Applicant Action41433833 ANDAs Approved66108 *The counts in this table include ANDAs that were subject to priority review under subparagraphs (A) and (D) of section 505(j)(11) of the FD&C Act, as added by section 801 of the Food and Drug Administration Reauthorization Act of 2017 (FDARA). FY 2026 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act First QuarterSecond QuarterThird QuarterFourth Quarter October - DecemberJanuary - MarchApril - JuneJuly - September ANDAs Awaiting FDA Action178179171173 ANDAs Awaiting Applicant Action178179186186 ANDAs Approved20212719 Number of Presubmission Meetings Requested0010 Number of Presubmission Meetings Held0000 Number of Product Development Meetings Requested2313 Number of Product Development Meetings Held2222 FY 2026 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act for which the Secretary has taken action pursuant to Section 506H(c)* First QuarterSecond QuarterThird QuarterFourth Quarter October - DecemberJanuary - MarchApril - JuneJuly - September ANDAs Approved1*3*2*2* * Section 807(5) of FDARA requires FDA to include information in this report on the effect section 506H of the FD&C Act may have had on the length of time for approval and the number of review cycles for ANDAs with a CGT designation for which FDA has taken action pursuant to section 506H(c) of the FD&C Act. As FDA explained in the guidance for industry Competitive Generic Therapies, the actions FDA may take to expedite development include, as appropriate, product development meetings and pre-submission meetings, and the actions FDA may take to expedite review include mid-cycle-review meetings, enhanced mid-cycle-review meetings and striving to act on the ANDA as soon as possible, including prior to the GDUFA goal date. In FY 2026, there were eight approved ANDAs for a CGT for which FDA took action to expedite the development and review of the applications; specifically, we held product development meetings with the applicants prior to submission of the ANDAs, held mid-review-cycle meetings with three of the applicants during the first review cycle, and took actions to expedite the review of the ANDAs. It is difficult to assess the effect the actions to expedite the development and review of these CGTs may have had on the length of time to approval and the number of review cycles for approval without a larger sample of applications, including applications for comparable products for which expedited development and review actions were not taken to use as a comparison group. We note, however, that seven of the ANDAs were approved after two or fewer review cycles and that the approval time for these ANDAs was faster than the mean approval time for the quarter in which they were approved. Of these, four were also approved faster than the median approval time for the quarter in which they were approved. Through our pre-ANDA program, the applicants for these ANDAs were able to receive targeted feedback on specific scientific issues or questions regarding their ANDA development program. The opportunity to obtain this kind of targeted advice from FDA likely shortened development time for the ANDAs and allowed the applicants to avoid deficiencies that may have led to a delay in the approval of the ANDAs. FY 2026 Pending Suitability Petitions under Section 505(j)(2) (C) of the FD&C Act+ FY 2026 Petitions Pending a Substantive FDA Response122 Petitions Pending a Substantive FDA Response for More than 180 Days of Receipt**61 +These numbers are reported annually and will be posted when available. **Note that petitions submitted prior to FY 2024 did not receive goal dates. Information about the performance of the generic drugs program on suitability petitions subject to goal dates, which began to apply for petitions submitted in FY 2024, will be included in annual GDUFA Performance Reports. Previous Activities Reports Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2025) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2024) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2023) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2022) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2021) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2020) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2019) Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2018) Content current as of: 11/12/2026 Regulated Product(s) Drugs
摘要 待译
Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).